Page last updated: 2024-08-26

fulvestrant and megestrol acetate

fulvestrant has been researched along with megestrol acetate in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (71.43)	29.6817
2010's	2 (28.57)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I	1
Parker, LM; Piccart, M; Pritchard, KI	1
Gorbunova, VA; Howell, A; Lichinitser, MR; Pienkowski, T; Robertson, JF; Watanabe, T	1
Cheung, KL; Owers, R; Robertson, JF	1
DiLeonardo, M; Gibbons, G; Resnik, KS	1
Batson, S; Jones, N; Livings, C; Telford, C	1

Reviews

2 review(s) available for fulvestrant and megestrol acetate

Article	Year
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:7 Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Down-Regulation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Megestrol Acetate; Middle Aged; Postmenopause; Prognosis; Quality of Life; Receptors, Estrogen; Tamoxifen	2003
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy. Clinical breast cancer, 2016, Volume: 16, Issue:3 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles	2016

Article

Year

Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:7

Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Down-Regulation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Megestrol Acetate; Middle Aged; Postmenopause; Prognosis; Quality of Life; Receptors, Estrogen; Tamoxifen

2003

Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.

Clinical breast cancer, 2016, Volume: 16, Issue:3

Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles

2016

Trials

2 trial(s) available for fulvestrant and megestrol acetate

Article	Year
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast cancer research and treatment, 2003, Volume: 79, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles	2003
Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre. Endocrine-related cancer, 2006, Volume: 13, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Postmenopause; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Tamoxifen; Treatment Outcome	2006

Article

Year

Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.

Breast cancer research and treatment, 2003, Volume: 79, Issue:2

Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles

2003

Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.

Endocrine-related cancer, 2006, Volume: 13, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Postmenopause; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Tamoxifen; Treatment Outcome

2006

Other Studies

3 other study(ies) available for fulvestrant and megestrol acetate

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast cancer research and treatment, 2005, Volume: 92, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Neoplasm Metastasis; Postmenopause; Retrospective Studies; Salvage Therapy; Tamoxifen; Treatment Outcome	2005
Clinically occult cutaneous metastases. Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:6 Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing	2006